Quantum-Si Q2 FY26 earnings call QSI

Quantum-Si has updated the Proteus launch timeline from the end of 2026 to the second quarter of 2027. This decision stems from an internal assessment to add an additional integrated instrument design cycle, aiming to reduce manufacturing risk, improve system repeatability, and strengthen product readiness for a positive customer experience at launch. The company believes this approach is more responsible and capital efficient, de-risking the platform before production.

The additional design cycle was prompted by learnings from integrated unit testing in H1 2026, which revealed execution risks in moving directly to production. The goal is to ensure consistent high performance across all machines and simplify manufacturing processes. This cycle involves finalizing design changes, rolling them through manufacturing, building, and testing the machines, expected to be completed by the end of 2026.

Progress in Recognizer development continues to meet expectations, with the internal developmental sequencing kit able to detect 17 amino acids. The revised instrument timeline provides additional time to progress further, with the company now expecting to deliver Proteus with a detection capability of either 19 or 20 amino acids at launch, an improvement from the previously anticipated 18.

The company is evolving its library preparation strategy from a single generic kit to a suite of application-oriented kits. This shift is based on real-world insights from Platinum customers and aims to provide more tailored, off-the-shelf tools, making implementation more efficient and reducing customer optimization. This approach is expected to deliver a broad range of capabilities faster and with lower technical risk.

The Platinum placement program has provided valuable market and technical insights. An example includes work with a biopharma customer on AAV serotyping for gene therapy, where Platinum data modeled expected Proteus performance to meet sensitivity requirements. This application alone suggests an attractive market opportunity given over 150 companies developing AAV-based gene therapies.

Learnings from Platinum commercial activities have identified a substantial non-human proteomics market opportunity, estimated at over $4 billion annually. This includes pathogen research and agricultural applications, where traditional techniques are not well-suited, and a defined reference is often unavailable. The company believes Proteus's core capabilities align well with these needs.

To preserve financial strength and align with the revised Proteus timeline, Quantum-Si announced operating expense actions, including a 20% reduction in force. These actions are designed to reduce cash burn, extend the capital runway into Q4 2028, and concentrate resources on critical Proteus readiness activities, ensuring disciplined funding over the extended timeline.